Novo Nordisk specializes in diabetes care and markets large number of diabetes products and also products in the areas of hemostasis management, growth hormone therapy and hoprmone replacement therapy. The company’s R&D is focused on therapeutic areas requiring superior protein-based therapies including diabetes, hemostasis, growth hormone treatment, chronic inflammation/autoimmune diseases and cancer. The company possess clinical pipeline of products that includes four products in phase 3, six products in phase 2 and five products in phase 1 and also has filed FDA for four products.